References
- Ampyra® (dalfampridine) extended release tablets [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; 2011
- Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K+ channels. Ann N Y Acad Sci 1999;868:233-85
- Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59
- Rudy B. Voltage-gated K+ channels. In: Kew J, Davies C, eds. Ion Channels, From Structure to Function. Oxford: Oxford University Press, 2010:21-57
- Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
- Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
- Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011;27:1415-23
- Lundh H, Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 1977;42:411-12
- Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84
- Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
- Vollmer T, Blight AR, Henney HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009;31:2215-23
- Vollmer T, Henney HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I–II, open-label trial. Clin Ther 2009;31:2206-14
- Smith W, Swan S, Marbury T, Henney HR. Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
- Henney HR 3rd, Blight A, Faust B. Effect of food on the single-dose pharmacokinetics of dalfampridine extended release tablets in healthy volunteers. Am J Health Syst Pharm 2011;68:2148-54
- Acorda Therapeutics: Data on file. PBR-974598. “Expert opinion on the metabolite profile of 14C-4-aminopyridine in human plasma and urine.” 1998
- Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508
- Wible BA, Kuryshev YA, Smith SS, et al. An ion channel library for drug discovery and safety screening on automated platforms. Assay Drug Dev Technol 2008;6:765-80
- Kuryshev YA, Bruening-Wright A, Brown AM, et al. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J Cardiovasc Pharmacol 2010;56:420-30
- Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2
- Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
- Stühmer W, Ruppersberg JP, Schröter KH, et al. Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain. EMBO J 1989;8:3235-44
- Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62